Viewing nowPMS Pregabalin Capsule 300 mg
Pregabalin 300mg
Hard capsule · Prescription medication
PharmaScience Korea Co., Ltd.

MFDS item code 201605664 · Approved 2016.09.27 · Insurance code 627600140
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, and treatment of fibromyalgia
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures in patients with epilepsy. Additionally, it is effective in the treatment of fibromyalgia. It helps improve symptoms of various neurological disorders.
This medication is administered orally, with or without food, in 2 divided doses per day, based on the total daily dose of pregabalin. Because this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, when discontinuing this medication, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Because the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. * For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered additionally as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behavior, so if there are signs of depression or mood changes during treatment, you should consult a doctor immediately. If you are allergic to any component of this medication, you should not take it, nor should it be administered to patients with certain hereditary metabolic disorders. Patients with diabetes should be cautious as weight gain may require adjustments in blood sugar control medications. In the case of severe allergic reactions such as angioedema, immediately stop taking the medication and inform healthcare professionals. Elderly patients are at increased risk of falls or injuries due to dizziness and drowsiness, and visual changes such as blurred vision have also been reported. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headaches, and anxiety; therefore, the dosage should be gradually reduced as per a doctor's instructions. Due to the risk of drug abuse, special caution is needed for patients with a history of mental disorders or substance abuse. Patients with impaired kidney function may require dosage adjustments for this medication. Patients with heart disease should be cautious as cardiovascular issues such as congestive heart failure may arise during treatment with this medication. When combined with other medications that may cause central nervous system depression, the risk of respiratory depression may increase, so caution is advised. In the early stages of pregnancy, there may be a risk of fetal malformation; hence, women who are pregnant or planning to become pregnant must consult a doctor and use effective contraception. Women who are breastfeeding should note that this medication may transfer into breast milk and affect the infant, so they should consult healthcare professionals about stopping breastfeeding or the medication. This medication may cause dizziness and drowsiness; therefore, caution should be exercised before driving or operating dangerous machinery. If severe rash or allergic reactions occur, immediately stop taking the medication and inform healthcare professionals. In case of overdose, symptoms such as confusion, drowsiness, and depression may appear, and treatments such as hemodialysis may be required if necessary. It should be stored safely out of the reach of children and avoiding transferring the medication to other containers is advised.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. Additionally, it is important to store it at room temperature between 15 and 30 degrees Celsius to maintain its efficacy.
A hard capsule with a brown-red upper part and a white lower part containing powder that is white or light yellow.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 300mg
Hard capsule · Prescription medication
PharmaScience Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.